Treatment modalities against the coronavirus disease 2019 (COVID-19) pandemic are limited in efficacy. This has led many centers to use
Why does convalescent plasma therapy for severe COVID-19 show mixed success?
Home » antibodies »
Why does convalescent plasma therapy for severe COVID-19 show mixed success?
Treatment modalities against the coronavirus disease 2019 (COVID-19) pandemic are limited in efficacy. This has led many centers to use
What is a protective neutralizing antibody titer against SARS-CoV-2 infection?
Caused by the worldwide spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the coronavirus disease 2019 (COVID-19) pandemic continues
What is a protective neutralizing antibody titer against SARS-CoV-2 infection?
Caused by the worldwide spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the coronavirus disease 2019 (COVID-19) pandemic continues
Natural virus-induced immunity protective against UK and South African SARS-CoV-2 variants in hamster study
As new variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue to emerge, fueling the continued spread of
SARS-CoV-2 can infect blood monocytes and trigger inflammation, finds study
Researchers found about 10% of blood monocytes in coronavirus disease 2019 (COVID-19) patients are infected with severe acute respiratory syndrome
Study reports lasting immune response in convalescent COVID-19 patients
Using different types of assays, researchers found both cellular and humoral immune responses for up to eight months in coronavirus
COVID Antibodies May Last Up to 5 Months
MONDAY, Nov. 2, 2020 — How long does a person who has had mild-to-moderate COVID-19 retain the antibodies that can
Study reveals antibodies against coronavirus stay in body for 60-80 days
A sero survey conducted at a leading hospital in New Delhi over five months has found that the prevalence of
Recovered coronavirus patients produce different types of antibodies
Coronavirus immunity may not be equal: Not all recovered patients develop the same antibodies against the virus – and most